CTOs on the Move

Revolution Medicines

www.revmed.com

 
REVOLUTION Medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. Our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. We pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.revmed.com
  • 700 Saginaw Drive
    Redwood City, CA USA 94063
  • Phone: 650.481.6801

Executives

Name Title Contact Details
Sapan Shenoy
Senior Director Information Technology Profile
Anthony Mancini
EVP & Chief Operating Officer Profile

Funding

Revolution Medicines raised $260.9M on 02/03/2021

Similar Companies

PrecisionMed

PrecisionMed Inc. is a Solana Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Seven Bridges

Personalized medicine, drug discovery, diagnostic testing, and foundational genomic research all start with bioinformatics. The world`s largest research institutions use Seven Bridges` software platform to help them analyze, store, and act on genomic and other biological data.

Chiron

Chiron Corporation was an American multinational biotechnology firm founded in 1981, based in Emeryville, California, that was acquired by Novartis on April 20, 2006.

Achillion Pharmaceuticals

Small publicly-traded Pharmaceutical company founded in 1998 located in New Haven, CT. Discovery and Clinical Development capabilities, specializing in anti-infectives. Several agents are in clinical trials for treating chronic hepatitis C infection..

MicuRx Pharmaceuticals

MicuRx mission is to discover and develop safer and more convenient antibiotics to combat drug-resistant bacterial infections. Multi-drug resistant (MDR) infections represent a major global threat to the public health, routinely forcing the use of antibiotics with high incidence of adverse effects. To combat resistant infections, physicians may increase dosing of antibiotics, or resort to less safe agents, pushing the safety envelope. Thus, healthcare providers and regulatory agencies increasingly face a difficult choice of balancing the risk of infection against unacceptably high adverse event rates from an effective but relatively toxic antibiotic. For example, in July 2016, FDA imposed a new labeling warning on the toxicity of fluoroquinolones, further restricting the use of this essential class, exemplified by anti-pseudomonal agent ciprofloxacin. Anti-MRSA agent linezolid (Zyvox®) is often used beyond its approved 14-day therapy, resulting in several myelosuppression-associated adverse effects listed in the black box warning for this important drug. MicuRx is addressing the critical need for effective but safer therapeutics by designing novel new compounds with reduced toxicity and adverse events while maintaining excellent clinical efficacy.